Bio-Gene Technology

Bio-Gene Technology Equity

The The Equity of Bio-Gene Technology (BGT.AX) as of Oct 11, 2026 is 2.09 M AUD. In the previous year, The Equity was 1.63 M AUD — a change of 28.49% (higher).

Equity

2.09 MAUD

YoY

28.49%

Last updated:

In 2026, Bio-Gene Technology's equity was 2.09 M AUD, a 28.49% increase from the 1.63 M AUD equity in the previous year.

The Bio-Gene Technology Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
4.95 M AUD
Jan 1, 2020
6.00 M AUD
Jan 1, 2021
4.25 M AUD
Jan 1, 2022
6.27 M AUD
Jan 1, 2023
3.22 M AUD
Jan 1, 2024
2.79 M AUD
Jan 1, 2025
1.63 M AUD
Jan 1, 2026
2.09 M AUD
The Bio-Gene Technology Equity history
YEAREquityYoY
2.09 MAUD+28.49%
1.63 MAUD-41.71%
2.79 MAUD-13.35%
3.22 MAUD-48.61%
6.27 MAUD+47.63%
4.25 MAUD-29.26%
6.00 MAUD+21.27%
4.95 MAUD-28.34%
6.91 MAUD-23.86%
9.07 MAUD+1,816.45%
473,349.00AUD+8.73%
435,360.00AUD+50.11%
290,030.00AUD—
Access this data via the Eulerpool API
Get Free API Key

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Bio-Gene Technology's Equity

Bio-Gene Technology's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bio-Gene Technology's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bio-Gene Technology's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bio-Gene Technology's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bio-Gene Technology’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bio-Gene Technology stock

The Equity of Bio-Gene Technology is 2.09 M AUD in 2026.

The Equity of Bio-Gene Technology changed from 1.63 M AUD to 2.09 M AUD, representing a 28.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Bio-Gene Technology historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Bio-Gene Technology

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Bio-Gene Technology